October 17, 2023
Company Description: VerImmune Inc (www.verimmune.com) is developing a highly innovative Virus-inspired Particle (ViP™) platform technology that has the potential to treat multiple diseases. VerImmune's primary focus lies in the field of Oncology, wherein the ViP technology enables a pioneering first-in-class cancer immunotherapy approach known as Anti-tumor Immune Redirection (AIR). This innovative method harnesses the body's pre-existing immune system, specifically by leveraging the immune memory from past infections or childhood vaccination to combat cancer. By taking a highly orthogonal approach, VerImmune's technology holds immense potential to revolutionize the Immuno-Oncology market, offering new treatment possibilities for patients facing limited options or resistance to current cancer therapies. Beyond Oncology, VerImmune is looking into other areas of high unmet needs via the utilization of ViPs with novel properties and/or payloads that exert highly disruptive mechanisms of action.
CEO/Top Company Official
Lead Product in Development
Development Phase of Primary Product